Determinants of rapamycin sensitivity in breast cancer cells.
about
The regulation of cyclin D1 degradation: roles in cancer development and the potential for therapeutic inventionRegulation and localization of ribosomal protein S6 kinase 1 isoformsThe mTOR signalling pathway in human cancerNext-generation mTOR inhibitors in clinical oncology: how pathway complexity informs therapeutic strategyThe role of HER2-targeted therapies in women with HER2-overexpressing metastatic breast cancerTargeting the mTOR signaling network for cancer therapyDetermining sensitivity to rapamycin and its analogues in breast cancer patientsTreating breast cancer through novel inhibitors of the phosphatidylinositol 3'-kinase pathway.Effects of combined treatment with rapamycin and cotylenin A, a novel differentiation-inducing agent, on human breast carcinoma MCF-7 cells and xenografts.The fate of chemoresistance in triple negative breast cancer (TNBC)Toward rapamycin analog (rapalog)-based precision cancer therapyTargeting insulin and insulin-like growth factor signaling in breast cancerTargeting triple-negative breast cancer: optimising therapeutic outcomesThe PI3K/Akt/mTOR pathway in ovarian cancer: therapeutic opportunities and challengesPI3K-AKT-mTOR-signaling and beyond: the complex network in gastroenteropancreatic neuroendocrine neoplasmsPredicting everolimus treatment efficacy in patients with advanced endometrial carcinoma: a GINECO group study.Cyclin D1 induction by benzo[a]pyrene-7,8-diol-9,10-epoxide via the phosphatidylinositol 3-kinase/Akt/MAPK- and p70s6k-dependent pathway promotes cell transformation and tumorigenesisRapamycin regulates stearoyl CoA desaturase 1 expression in breast cancerColocalized delivery of rapamycin and paclitaxel to tumors enhances synergistic targeting of the PI3K/Akt/mTOR pathway.Rapamycin delays growth of Wnt-1 tumors in spite of suppression of host immunity.Deciphering downstream gene targets of PI3K/mTOR/p70S6K pathway in breast cancerAn approach to analyse the specific impact of rapamycin on mRNA-ribosome association.Temsirolimus and rituximab in patients with relapsed or refractory mantle cell lymphoma: a phase 2 study.Phase 2 trial of everolimus and carboplatin combination in patients with triple negative metastatic breast cancerA phase II study of everolimus (RAD001), an mTOR inhibitor plus CHOP for newly diagnosed peripheral T-cell lymphomas.Comparison of Akt/mTOR signaling in primary breast tumors and matched distant metastasesBiomarker Development for the Clinical Activity of the mTOR Inhibitor Everolimus (RAD001): Processes, Limitations, and Further ProposalsMammalian target of rapamycin inhibition abrogates insulin-mediated mammary tumor progression in type 2 diabetes.Intracellular parasitism with Toxoplasma gondii stimulates mammalian-target-of-rapamycin-dependent host cell growth despite impaired signalling to S6K1 and 4E-BP1.Rapamycin inhibits cell proliferation in type I and type II endometrial carcinomas: a search for biomarkers of sensitivity to treatment.The PI3K/AKT/mTOR pathway in breast cancer: targets, trials and biomarkers.Targeted inhibition of mammalian target of rapamycin signaling inhibits tumorigenesis of colorectal cancerRapamycin sensitizes Akt inhibition in malignant human breast epithelial cells.The combination of gefitinib and RAD001 inhibits growth of HER2 overexpressing breast cancer cells and tumors irrespective of trastuzumab sensitivityCombined SFK/mTOR inhibition prevents rapamycin-induced feedback activation of AKT and elicits efficient tumor regression.Targeting the translational apparatus to improve leukemia therapy: roles of the PI3K/PTEN/Akt/mTOR pathway.Predictive biomarkers for the activity of mammalian target of rapamycin (mTOR) inhibitors.Akt activation is a common event in pediatric malignant gliomas and a potential adverse prognostic marker: a report from the Children's Oncology Group.Inhibition of p70 S6 kinase (S6K1) activity by A77 1726 and its effect on cell proliferation and cell cycle progress.The translational response of the human mdm2 gene in HEK293T cells exposed to rapamycin: a role for the 5'-UTRs.
P2860
Q21245733-23579CF1-8D9E-4EDB-A951-6931455BA0A7Q24336314-8DC64D43-B71A-4F91-8214-9D0B05B4CCDDQ24627306-38FBEA86-1A1B-4C47-A299-87AEBA85E964Q24628724-E59D8170-6CB6-4D88-9D4E-FA872826BCD4Q24656159-3328911E-7C35-4133-BA93-76DC8186650AQ24658334-7777C1BB-F7D3-47FD-88DB-DFE6D78B943FQ24797136-088F555A-27F3-43EC-AEBB-2C9DAB44DA2FQ24813788-07E1B522-0E73-4C98-9C4E-4BCDBA2BB726Q25257700-CAB2EDDA-216D-4ED9-8D94-818EECB9B085Q26775232-E8F7183D-56A9-4CBD-B059-AD0C138F5E99Q26795606-B8C73FC3-B3B1-440A-84E6-331E147E05CBQ26826380-B6232201-5047-401E-85D5-173D89D9096EQ26850892-1F88FD25-2D97-4B41-A0F0-FC81DE8FE882Q26851852-27380ED8-CEEE-450E-A112-921EE954EB97Q26862544-82ED8C3C-7B61-4B03-B18F-B97713F25644Q27851999-0081F9C3-2717-480D-AB78-C0A673AE2EE8Q28749707-3BEEE5A8-966B-4587-AD69-67AEA4B34694Q30430510-13867930-61C0-4317-BADA-8EA623818A7CQ30583249-BF11070C-D4F4-44A1-B336-000A45375CFFQ33345588-516D5D81-CA8D-4A2E-92D6-E2A66A62AD43Q33354798-68A4FA63-63F7-4E35-9846-45DC3518B6E0Q33357019-B28B4F7C-8EE9-4D0A-BB19-A3DD4BF33F0CQ33394663-C33E019A-82B1-4580-A564-5922AB5BC3F2Q33414349-F329C193-B74F-4132-95F0-2211ECBEA88FQ33429898-3FB8F6C0-1C52-4607-86FC-022F3301ACA8Q33640816-F35497EF-94E4-4F29-9CF2-46DA0AEDE21AQ33760578-03F48DAA-BBCF-403E-887B-AC6CF2512848Q33849666-70FCD87B-3825-4DBE-ACE6-4BC76887CA14Q33894468-2F749CD0-1CD7-45C1-9932-494E9C373066Q33903478-5167C388-CE6B-4EFE-BDA7-BFE9C9723205Q33937368-A62EC744-6EE5-4C06-B22F-CC8A5C8818C7Q33967933-2B2B5649-86A0-4E8C-A632-511FFD124C9BQ34005315-D697143B-2E1F-4FC4-B70E-39D7CC6D271BQ34036041-A73CDC5E-D682-432D-A4EB-070E96EEB92BQ34135475-4C11378D-B926-43AD-A0B8-CCF744157192Q34173253-4A80E7AA-B21B-4A8E-B5B2-9CD64EE6822FQ34181598-E6B84609-E0EC-4D20-B8C8-C5080F784BE7Q34196216-30216168-43A2-4EB3-94BD-0D038054F9F8Q34417518-8C519C59-D326-4D25-9600-7BB86E6F10C1Q34559580-62A216A4-EFC1-4BA7-A36E-C79B0458F737
P2860
Determinants of rapamycin sensitivity in breast cancer cells.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Determinants of rapamycin sensitivity in breast cancer cells.
@en
type
label
Determinants of rapamycin sensitivity in breast cancer cells.
@en
prefLabel
Determinants of rapamycin sensitivity in breast cancer cells.
@en
P2093
P1476
Determinants of rapamycin sensitivity in breast cancer cells.
@en
P2093
Gordon B Mills
Haixia Zhang
JinJiang Dong
Junying Peng
Mien-Chie Hung
Wallace H Mondesire
Weiguo Jian
Woo-Chul Noh
P304
P356
10.1158/1078-0432.CCR-03-0043
P407
P577
2004-02-01T00:00:00Z